Addressing Obesity During Psoriasis Patient Consultations
-
By
-
Joana Nicolau
-
Anna López-Ferrer
-
Pablo de la Cueva
-
February 2, 2026
-
Clinical Scorecard: Addressing Obesity During Psoriasis Patient Consultations
At a Glance
| Category | Detail |
|---|
| Condition | Psoriasis and obesity |
| Key Mechanisms | Chronic inflammatory state, proinflammatory cytokines, insulin resistance |
| Target Population | Patients with psoriasis, particularly those with obesity |
| Care Setting | Multidisciplinary healthcare settings |
Key Highlights
- Up to 50% of psoriasis patients are obese, increasing cardiovascular risk and disease severity.
- GLP-1 RAs and tirzepatide show significant weight loss and improved psoriasis severity.
- No specific guidelines exist for managing obesity in psoriasis patients.
Guideline-Based Recommendations
Diagnosis
- Assess BMI and waist circumference to identify obesity in psoriasis patients.
Management
- Implement lifestyle modifications, pharmacological treatments (GLP-1 RAs), and consider bariatric surgery.
Monitoring & Follow-up
- Follow-up on weight-related outcomes during biologic therapy.
Risks
- Increased cardiovascular disease risk associated with both psoriasis and obesity.
Patient & Prescribing Data
Patients with psoriasis and comorbid obesity
GLP-1 RAs can reduce psoriasis severity and improve metabolic health.
Clinical Best Practices
- Adopt a patient-centered communication approach to discuss weight.
- Encourage early detection of excess adiposity in dermatology consultations.
- Utilize a multidisciplinary approach for optimal management.
References
